, Tracking Stock Market Picks
Enter Symbol:
Eclipsys Corporation (ECLP) [hlAlert]

down 19.68 %

Eclipsys Corporation (ECLP) rated Buy

Posted on: Wednesday,  Aug 22, 2007  9:25 AM ET by Avondale Partners

Avondale Partners rated Buy Eclipsys Corporation (NASDAQ: ECLP) on 08/22/2007, when the stock price was $23.06. Since
then, Eclipsys Corporation has lost 19.69% as of 08/24/2010's recent price of $18.52.
If you would have followed this Avondale Partners's recommendation on ECLP, you would have lost 19.68% of your investment in 1098 days.

Eclipsys Corporation is a healthcare information technology companydelivering solutions that enable healthcare providers to achieve improvedclinical, financial and administrative outcomes. Eclipsys offers an integrated suite of healthcare products in five critical areas -- clinical management, access management, patient financial management, strategic decision support and integration. Eclipsys' products have been designed to deliver a measurable impact on outcomes, enabling Eclipsys' customers to quantify clinical benefits and return on investment.

Avondale’s research analysts are charged with producing high quality, independent, value-added, and timely investment analysis / advice. The firm’s strategy is to deemphasize maintenance research, and instead direct the overwhelming majority of our efforts on developing well-constructed, actionable recommendations, in part by leveraging proprietary networks of industry contacts. Avondale’s growing research department now totals 25 professionals. Senior analysts average 14 years of industry experience and are routinely recognized by a variety of nationally known rating entities. In the last two years, Avondale Analysts were named to the Wall Street Journal’s Best on the Street poll as well as’s Top Analyst Rankings.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/22/2007 9:25 AM Buy
23.06 27.00
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD down  -9.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy